Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.

Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH.

JAMA Neurol. 2015 Oct;72(10):1139-47. doi: 10.1001/jamaneurol.2015.1807.

2.

Growth factor gene therapy for Alzheimer disease.

Tuszynski MH, U HS, Alksne J, Bakay RA, Pay MM, Merrill D, Thal LJ.

Neurosurg Focus. 2002 Nov 15;13(5):e5. Review.

PMID:
15769074
3.

Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals.

Salmon DP, Thomas RG, Pay MM, Booth A, Hofstetter CR, Thal LJ, Katzman R.

Neurology. 2002 Oct 8;59(7):1022-8.

PMID:
12370456
4.

Nerve growth factor gene therapy for Alzheimer's disease.

Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, Vahlsing HL.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):207. No abstract available.

PMID:
12212782
5.

Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks?

Katzman R, Galasko DR, Saitoh T, Chen X, Pay MM, Booth A, Thomas RG.

Neurology. 1996 Mar;46(3):889-91. No abstract available.

PMID:
8618734
6.

The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, et al.

Neurology. 1990 Jan;40(1):1-8.

PMID:
2153271

Supplemental Content

Support Center